These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10999222)

  • 1. Rationale for immune-based therapies for human immunodeficiency virus type 1 infection.
    Lederman MM; Valdez H
    AIDS Clin Rev; 2000-2001; ():229-61. PubMed ID: 10999222
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies.
    Sereti I; Lane HC
    Clin Infect Dis; 2001 Jun; 32(12):1738-55. PubMed ID: 11360217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of HIV-1 infection by soluble factors of the immune response.
    DeVico AL; Gallo RC
    Nat Rev Microbiol; 2004 May; 2(5):401-13. PubMed ID: 15100693
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunopathogenesis and immunotherapy in AIDS virus infections.
    Letvin NL; Walker BD
    Nat Med; 2003 Jul; 9(7):861-6. PubMed ID: 12835706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can immune responses to human immunodeficiency virus be preserved, enhanced, or restored?
    Walker BD
    AIDS Clin Rev; 2000-2001; ():101-14. PubMed ID: 10999218
    [No Abstract]   [Full Text] [Related]  

  • 6. Improving immune function and controlling viral replication in HIV-1-infected patients with immune-based therapies.
    Angel JB
    AIDS Read; 2001 Apr; 11(4):209-21. PubMed ID: 11392678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for AIDS virus infections: cautious optimism for cell-based vaccine.
    Bhardwaj N; Walker BD
    Nat Med; 2003 Jan; 9(1):13-4. PubMed ID: 12514710
    [No Abstract]   [Full Text] [Related]  

  • 8. Cellular immunotherapy for cytomegalovirus and HIV-1 infection.
    Van den Bosch GA; Ponsaerts P; Vanham G; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
    J Immunother; 2006; 29(2):107-21. PubMed ID: 16531812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
    Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular and molecular interactions in HIV infections: a review.
    Tumbo-Oeri AG; Omwandho CA
    East Afr Med J; 2002 May; 79(5):249-53. PubMed ID: 12638808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human xenograft models for virus infection.
    Mosier DE
    Virology; 2000 Jun; 271(2):215-9. PubMed ID: 10860873
    [No Abstract]   [Full Text] [Related]  

  • 12. [Gene therapy in HIV infection and other viral infections].
    Frøland SS
    Tidsskr Nor Laegeforen; 2001 Feb; 121(4):473-8. PubMed ID: 11255866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients.
    Mitsuyasu R
    J Infect Dis; 2002 May; 185 Suppl 2():S115-22. PubMed ID: 12001032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune strategy.
    Proj Inf Perspect; 2004 Jan; (37):21-3. PubMed ID: 15119287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy.
    Kulkosky J; Pomerantz RJ
    Clin Infect Dis; 2002 Dec; 35(12):1520-6. PubMed ID: 12471572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No differences in cellular immune responses between asymptomatic HIV type 1- and type 2-infected Gambian patients.
    Jaye A; Sarge-Njie R; Schim van der Loeff M; Todd J; Alabi A; Sabally S; Corrah T; Whittle H
    J Infect Dis; 2004 Feb; 189(3):498-505. PubMed ID: 14745708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salk's HIV immunogen: an immune-based therapy in human trials since 1988.
    Crit Path AIDS Proj; 1994-1995 Winter; (No 30):1, 20-3. PubMed ID: 11362152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral and host factors in the pathogenesis of HIV infection.
    Derdeyn CA; Silvestri G
    Curr Opin Immunol; 2005 Aug; 17(4):366-73. PubMed ID: 15955686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A boost for the immune system.
    TreatmentUpdate; 1998 Nov; 10(9):3-4. PubMed ID: 11365925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immune-based therapies and HIV infection].
    Weiss L
    Ann Med Interne (Paris); 2002 Jun; 153(4):227-36. PubMed ID: 12218888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.